At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 6, 2026 at 08:00 ET
Praxis Precision Medicines announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with SCN2A developmental and epileptic encephalopathy (DEE), showing a 77% placebo-adjusted seizure reduction (p=0.015) and meaningful functional improvements across sleep, motor function, and attention. The drug was well-tolerated with no drug-related serious adverse events, supporting its potential as a first disease-modifying therapy for this rare genetic epilepsy.
- Elsunersen achieved 77% placebo-adjusted seizure reduction (p=0.015) in SCN2A-DEE patients
- 71% of treated patients had >50% seizure reduction; 57% had at least 28 days seizure-free
- 100% of elsunersen patients showed functional improvements vs. none in placebo
- No treatment-emergent or serious adverse events related to the drug
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access